Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medtronic Endovascular
With
Medtronic
The study is being conducted to collect the 30-day safety data on the stent delivery system for all subjects enrolled into the study (with a minimum of 50 subjects enrolled) as well as the long-term 9-month safety and efficacy data on all subjects enrolled (with a minimum of 10 subjects enrolled into the study having the 120mm length stent implanted).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The lesion(s) is either de-novo or restenotic in nature, located in either the common iliac artery or the external iliac artery and is \>50% stenosed
Target vessel reference diameter ≥ 4.5 mm and ≤ 9.5 and can accommodate stent diameters of 6.0 - 10.0mm
Subject is either asymptomatic with a lesion stenosis ≥70% or symptomatic with a lesion stenosis ≥50% with an Ankle Brachial Index (ABI) \< 0.90 or Toe Brachial Index (TBI) \<0.80 or an abnormal Pulse Volume Recording (PVR);
Total lesion length is \< 110 mm;
You may not be if
Excessive Peripheral Vascular Disease (PVD), unresolved fresh thrombus or tortuosity or a target lesion/vessel that is heavily calcified ;
Tissue loss in the extremity: category 5 or 6 on the Rutherford scale;
Target lesion has a previous stent, or is within a prosthetic vascular bypass graft or within 1 cm of a graft anastomosis;
Target lesion is within an aneurysm or associated with an aneurysm in the vessel segment proximal or distal to the target lesion;
Lesion requires treatment with a non-standard device associated with Percutaneous Transluminal Angioplasty (PTA) prior to stent placement;
Inadequate distal run-off;
Planned interventional procedure or vascular surgery to target vessel within 30 days pre- or post-index iliac procedure;
History of bleeding diatheses or coagulopathy or will refuse blood transfusions;
Platelet count \<50,000 cells/mm3 or \>700,000 cells/mm3, or White Blood Count (WBC) \<3,000 cells/mm3;
Creatinine \>2.0 mg/dl;
Participation in another investigational device or drug study and has not completed the primary endpoint(s) follow-up phase of that study at least 30 days prior to enrollment in this trial or the subject has previously been enrolled in this Registry;
